Showing 3721-3730 of 5773 results for "".
- EyeCare Partners Expands Presence in Virginia with Two Acquisitionshttps://modernod.com/news/eyecare-partners-expands-presence-in-virginia-with-two-acquisitions/2480998/EyeCare Partners (ECP) announced it has entered into an agreement to partner with Commonwealth Eye Care Associates (CECA) and Retina Institute of Virginia (RIV). Financial terms of the deals were not disclosed. Through the partnership with Commonwealth Eye Care Associates, ECP
- NovaBay Pharmaceuticals Targets New Market with Antimicrobial Avenova Lid and Lash Spray for Lash Extensionshttps://modernod.com/news/novabay-pharmaceuticals-targets-new-market-with-antimicrobial-avenova-lid-and-lash-spray-for-lash-extensions/2480997/NovaBay Pharmaceuticals announced the launch of a new marketing campaign targeting the large and growing number of women who wear eyelash extensions. This campaign represents the first step in a larger growth initiative to introduce the Avenova brand to an new group of consumers.</
- Phase 4 Paladin Study Confirms Safety of Iluvien Treatment and Reduced Burden of Care For DME Patientshttps://modernod.com/news/paladin-phase-4-study-confirms-safety-of-durable-iluvien-treatment-and-reduces-burden-of-care-for-dme-patients/2480992/Alimera Sciences announced that the PALADIN phase 4 study confirms the safety of Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant and provides a durable treatment option that reduces the frequency of recurrence for patients wit
- Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-completes-dosing-in-oasis-phase-12a-clinical-trial-of-cls-ax-in-wet-amd-patients/2480989/Clearside Biomedical announced today completion of dosing in Cohorts 3 and 4 of OASIS, its phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicen
- B+L Enrolls First Patient in LASIK Trial Evaluating Technolas Teneo Excimer Laser for Vision Correction Surgery for Hyperopia with Astigmatismhttps://modernod.com/news/bausch-lomb-enrolls-first-patient-in-lasik-clinical-trial-evaluating-use-of-technolas-teneo-excimer-laser-for-vision-correction-surgery-for-hyperopia-with-astigmatism/2480988/Bausch + Lomb announced that the company has enrolled the first patient in a study evaluating the safety and efficacy of the Technolas Teneo excimer laser for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for hyperopia with astigmatism. &quo
- Schwind Eye-Tech Solutions Receives Funding for Laser Surgery Projecthttps://modernod.com/news/schwind-eye-tech-solutions-receives-funding-for-laser-surgery-project/2480987/Schwind eye-tech-solutions announced funding for a new research project aimed at developing an ophthalmic laser system with ultra-short laser pulses[1]. Schwind is planning initial investment in basic research of more than 1.6 million euros, of which around 52% is funding from
- Bausch + Lomb CEO Joseph C. Papa to Step Downhttps://modernod.com/news/joseph-c-papa-to-step-down-from-ceo-role-at-bausch-lomb/2480983/Bausch + Lomb announced Joseph C. Papa has stepped down as chair of the Board of Directors and plans to step down as CEO. The board appointed Thomas W. Ross, Sr., to serve as the chair, and has begun a search for a new CEO. Mr. Papa will remain as CEO and as a member of the bo
- Opus Genetics Expands its Leadership Teamhttps://modernod.com/news/opus-genetics-expands-its-leadership-team/2480981/Opus Genetics, a gene therapy company developing treatments for inherited retinal diseases, announced the appointments of Vikram Arora, PhD, DABT, as Vice President of Non-Clinical Development; Erin O’Neil, MD, as Vice President of Clinical Development; and Sarah Tuller, JD, RAC, as Vice Pr
- Report: Diagnosed Cases of AMD in the Seven Major Markets Expected to Grow Over Next 10 Yearshttps://modernod.com/news/report-diagnosed-cases-of-amd-in-the-seven-major-markets-expected-to-grow-over-next-10-years/2480979/Diagnosed prevalent cases of age-related macular degeneration (AMD) in the seven major markets combined is expected to increase from 33.66 million cases in 2021 to 40.32 million in 2031, at an annual growth rate (AGR) of 1.98%, according to GlobalData. Of the seven major mark
- Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseaseshttps://modernod.com/news/avista-therapeutics-partners-with-roche-to-develop-next-generation-aav-gene-therapy-vectors-for-ocular-diseases/2480977/Avista Therapeutics, which recently launched as a spinout of the University of Pittsburgh Medical Center (UPMC), announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. The partnership aims to apply Avista’s single-cell adeno-associated